Trial Profile
Comparative Study of Adalimumab and Infliximab as Induction and Maintenance Therapy for Crohn's Disease: A Retrospective Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- 06 Sep 2017 New trial record